Vinorelbine and epirubicin in metastatic breast cancer. A dose finding study

被引:17
|
作者
Blomqvist, C
Hietanen, P
Teerenhovi, L
Rissanen, P
机构
[1] Department of Radiotherapy and Oncology, University of Helsinki, FIN-00290 Helsinki
关键词
breast neoplasm; chemotherapy; metastases;
D O I
10.1016/0959-8049(95)00416-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aim of the study was to define the maximum tolerated dose (MTD) of vinorelbine given as one or two weekly doses in combination with epirubicin 60 mg/m(2) every third week. The MTD was defined as the dose resulting in a WHO grade III or IV leucopenia exceeding 50% of patients. Patients were treated in groups of 10 at escalating doses of vinorelbine. The number of patients at the final dose level was expanded to 20. The dose of epirubicin was kept constant at 60 mg/m(2) every third week. At dose level 1, 15 mg/m(2) vinorelbine was given on day 1 at level 2, 20 mg/m(2) was given on day 1 and at level 3, 20 mg/m(2) was given on days 1 and 8. The MTD was reached at dose level 3. WHO haematological toxicity grade IV occurred in 0, 10 and 45% and grade III at 60, 30 and 30% of patients at dose levels 1, 2 and 3, respectively. Despite the common occurrence of grade IV haematological toxicity, only two serious infections were noted. Non-haematological toxicity of vinorelbine included neurotoxicity, manifesting as muscle weakness, constipation and paresthesias in the majority of patients. Neurotoxicity was usually mild and did not require treatment discontinuation. Phlebitis at the injection site was troublesome in many patients. Alopecia and nausea, probably due to epirubicin, occurred in most patients. The response rates were 22% (95% CI (confidence interval) 3-60%), 40% (12-74%) and 60% (36-81%) at levels 1, 2 and 3, respectively (non-significant).
引用
收藏
页码:2406 / 2408
页数:3
相关论文
共 50 条
  • [41] Fixed dose, dose-dense capecitabine in metastatic breast cancer.
    O'Dea, Anne
    Khan, Meshaal
    Haines, Haley Isabela
    Kimler, Bruce F.
    Nye, Lauren Elizabeth
    Sharma, Priyanka
    Khan, Qamar J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [42] Epirubicin and ifosfamide in metastatic breast cancer
    Becher, R
    Kloke, O
    Hayungs, J
    Hartwich, G
    Bartels, H
    Szanto, J
    Wolf, E
    Illiger, HJ
    Halabi, S
    Rieche, K
    Hering, KG
    Ohl, S
    DeDycker, R
    Huhn, R
    Fischedick, AR
    Hofeler, H
    Pielken, HJ
    Hawig, I
    Hirche, H
    Seeber, S
    SEMINARS IN ONCOLOGY, 1996, 23 (03) : 28 - 33
  • [43] Oral vinorelbine in metastatic breast cancer
    Conte, PF
    Giovannelli, S
    BREAST CANCER RESEARCH, 2005, 7 : S15 - S16
  • [44] Oral vinorelbine in metastatic breast cancer
    PF Conte
    S Giovannelli
    Breast Cancer Research, 7 (Suppl 1)
  • [45] Capecitabine and vinorelbine in metastatic breast cancer
    Chan, Arlene
    Verrill, Mark
    EUROPEAN JOURNAL OF CANCER, 2009, 45 (13) : 2253 - 2265
  • [46] Vinorelbine, epirubicin and fluorouracil as first-line therapy in metastatic breast cancer - A phase II trial
    Elomaa, I
    Joensuu, H
    Blomqvist, C
    ACTA ONCOLOGICA, 2003, 42 (04) : 309 - 314
  • [47] Cytoxan, epirubicin and vinorelbine (CEN) in metastatic breast cancer (MBC): A phase II study of the Grupo Oncologico del Norte (GON)
    Lacave, AJ
    Esteban, E
    de Sande, LMG
    Carrasco, J
    Muniz, I
    Fra, J
    Palacio, I
    Vieitez, JM
    Puerta, J
    Buesa, JM
    ANNALS OF ONCOLOGY, 1998, 9 : 25 - 26
  • [48] Comparison of epirubicin and vinorelbine with cyclophosphamide, epirubicin, and fluorouracil as neoadjuvant chemotherapy for operable breast cancer
    Han, S.
    Kwak, K.
    Kim, J.
    Kim, J.
    Park, K.
    EJC SUPPLEMENTS, 2005, 3 (02): : 122 - 122
  • [49] Mitomycin (M), epirubicin (E) and vinorelbine (V) first-line chemotherapy for metastatic breast cancer (MBC). A feasibility study
    Neri, A
    Guarnieri, A
    Tucci, E
    Pepi, F
    Mazzocchi, B
    Algeri, R
    EUROPEAN JOURNAL OF CANCER, 1998, 34 : S44 - S44
  • [50] Phase I study of Doxil and vinorelbine in metastatic breast cancer
    Burstein, HJ
    Ramirez, MJ
    Petros, WP
    Clarke, KD
    Warmuth, MA
    Marcom, PK
    Matulonis, UA
    Parker, LM
    Harris, LN
    Winer, EP
    ANNALS OF ONCOLOGY, 1999, 10 (09) : 1113 - 1116